Cargando…

Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib

BACKGROUND: Little is known about the factors that predict for gastrointestinal stromal tumor (GIST) recurrence in patients treated with adjuvant imatinib. METHODS: Risk factors for GIST recurrence were identified, and 2 risk stratification scores were developed using the database of the Scandinavia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Joensuu, Heikki, Eriksson, Mikael, Hall, Kirsten Sundby, Hartmann, Jörg T, Pink, Daniel, Schütte, Jochen, Ramadori, Giuliano, Hohenberger, Peter, Duyster, Justus, Al-Batran, Salah-Eddin, Schlemmer, Marcus, Bauer, Sebastian, Wardelmann, Eva, Sarlomo-Rikala, Maarit, Nilsson, Bengt, Sihto, Harri, Ballman, Karla V, Leinonen, Mika, DeMatteo, Ronald P, Reichardt, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4209960/ https://www.ncbi.nlm.nih.gov/pubmed/24737415 http://dx.doi.org/10.1002/cncr.28669

Ejemplares similares

SLUG transcription factor: a pro-survival and prognostic factor in gastrointestinal stromal tumour
por: Pulkka, Olli-Pekka, et al.
Publicado: (2017)

KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial
por: Joensuu, Heikki, et al.
Publicado: (2023)

Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment
por: Ihle, Michaela Angelika, et al.
Publicado: (2018)

Fibrinogen‐like protein 2 in gastrointestinal stromal tumour
por: Pulkka, Olli‐Pekka, et al.
Publicado: (2022)

Tumor-infiltrating lymphocytes and outcome in Merkel cell carcinoma, a virus-associated cancer
por: Sihto, Harri, et al.
Publicado: (2012)

Preservation of Organ Function in Locally Advanced Non-Metastatic Gastrointestinal Stromal Tumors (GIST) of the Stomach by Neoadjuvant Imatinib Therapy
por: Vassos, Nikolaos, et al.
Publicado: (2021)

Activity and side effects of imatinib in patients with gastrointestinal stromal tumors: data from a german multicenter trial
por: Schlemmer, M, et al.
Publicado: (2011)

KIT and PDGFRA Variants and the Survival of Patients with Gastrointestinal Stromal Tumor Treated with Adjuvant Imatinib
por: Joensuu, Heikki
Publicado: (2023)

Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions
por: Bauer, Sebastian, et al.
Publicado: (2015)

Expression of KIT Receptor Tyrosine Kinase in Endothelial Cells of Juvenile Brain Tumors
por: Puputti, Marjut, et al.
Publicado: (2009)

Clinical relevance of integrin alpha 4 in gastrointestinal stromal tumours
por: Pulkka, Olli‐Pekka, et al.
Publicado: (2018)

Combination of Trabectedin and Gemcitabine for Advanced Soft Tissue Sarcomas: Results of a Phase I Dose Escalating Trial of the German Interdisciplinary Sarcoma Group (GISG)
por: Kasper, Bernd, et al.
Publicado: (2015)

Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors
por: Benjamin, Robert S., et al.
Publicado: (2010)

Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors
por: Bauer, S, et al.
Publicado: (2014)

Long-term prognosis of breast cancer detected by mammography screening or other methods
por: Lehtimäki, Tiina, et al.
Publicado: (2011)

Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer
por: Konsti, Juho, et al.
Publicado: (2011)

L-type calcium channels regulate filopodia stability and cancer cell invasion downstream of integrin signalling
por: Jacquemet, Guillaume, et al.
Publicado: (2016)

Benefit of pazopanib in advanced gastrointestinal stromal tumours: results from a phase II trial (SSG XXI, PAGIST)
por: Eriksson, M., et al.
Publicado: (2021)

Natural history of bleeding and characteristics of early bleeders among warfarin initiators – a cohort study in Finland
por: Rikala, Maria, et al.
Publicado: (2016)

Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study
por: Sihto, Harri, et al.
Publicado: (2011)

MASTL is enriched in cancerous and pluripotent stem cells and influences OCT1/OCT4 levels
por: Närvä, Elisa, et al.
Publicado: (2022)

Ten Years of Treatment with 400 mg Imatinib per Day in a Case of Advanced Gastrointestinal Stromal Tumor
por: Cameron, Silke, et al.
Publicado: (2011)

Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816H
por: Revheim, Mona-Elisabeth, et al.
Publicado: (2013)

Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study
por: Vincenzi, Bruno, et al.
Publicado: (2022)

Positron Emission Tomography as a Surrogate Marker for Evaluation of Treatment Response in Patients with Desmoid Tumors under Therapy with Imatinib
por: Kasper, Bernd, et al.
Publicado: (2013)

The Merendino procedure following preoperative imatinib mesylate for locally advanced gastrointestinal stromal tumor of the esophagogastric junction
por: Staiger, Wilko I, et al.
Publicado: (2008)

Vulnerability of invasive glioblastoma cells to lysosomal membrane destabilization
por: Le Joncour, Vadim, et al.
Publicado: (2019)

Deep learning identifies morphological features in breast cancer predictive of cancer ERBB2 status and trastuzumab treatment efficacy
por: Bychkov, Dmitrii, et al.
Publicado: (2021)

Outcome and biomarker supervised deep learning for survival prediction in two multicenter breast cancer series
por: Bychkov, Dmitrii, et al.
Publicado: (2022)

Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib
por: Joensuu, Heikki, et al.
Publicado: (2017)

Perspectives on the Management of Oligometastatic Disease in Esophago-Gastric Cancer
por: Goetze, Thorsten Oliver, et al.
Publicado: (2022)

Treatment of Angiosarcoma with Pazopanib and Paclitaxel: Results of the EVA (Evaluation of Votrient(®) in Angiosarcoma) Phase II Trial of the German Interdisciplinary Sarcoma Group (GISG-06)
por: Pink, Daniel, et al.
Publicado: (2021)

Prokineticins and Merkel cell polyomavirus infection in Merkel cell carcinoma
por: Lauttia, S, et al.
Publicado: (2014)

Quantitative Mass Spectrometry Imaging Reveals Mutation Status-independent Lack of Imatinib in Liver Metastases of Gastrointestinal Stromal Tumors
por: Abu Sammour, Denis, et al.
Publicado: (2019)

Normal stroma suppresses cancer cell proliferation via mechanosensitive regulation of JMJD1a-mediated transcription
por: Kaukonen, Riina, et al.
Publicado: (2016)

Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry
por: Wirtz, Ralph M., et al.
Publicado: (2016)

SORLA regulates endosomal trafficking and oncogenic fitness of HER2
por: Pietilä, Mika, et al.
Publicado: (2019)

HSP90 expression is associated with outcome in pulmonary carcinoid tumor patients
por: Niinimäki, Jenni, et al.
Publicado: (2023)

Imatinib potentiates anti-tumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
por: Balachandran, Vinod P., et al.
Publicado: (2011)

Bullous Pemphigoid Occurring after Stopping Imatinib Therapy of CML: Is a Continuation of Post-Treatment Follow-Up Needed?
por: Yakobson, Alexander, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1bfo05ge6k78snhfa4r09ffjjf